

Sweden Pharmaceuticals and Healthcare Report Q3 2015

<https://marketpublishers.com/r/SFEB59F6ACBEN.html>

Date: May 2015

Pages: 121

Price: US\$ 1,295.00 (Single User License)

ID: SFEB59F6ACBEN

Abstracts

Includes 3 FREE quarterly updates

BMI View: Private healthcare providers are to face an increasingly challenging business environment in Sweden. In October 2014, the newly elected government reached an agreement on initiatives aimed at imposing further restrictions on private companies engaged in publicly funded healthcare, care and educational services - and, as part of that limit, their right to distribute profits. This may result in reduced private investment in the country's healthcare sector and may potentially result in diminished innovation as well as capacity problems. In April 2015, the first regional council ordered its officials to find ways to limit the profits private companies can reap from running publicly-funded health services.

Headline Expenditure Projections

Pharmaceuticals: SEK36.41bn (USD5.31bn) in 2014 to SEK36.62bn (USD4.43bn) in 2015; +0.57% in local currency terms and -16.6% in US dollar terms.

Healthcare: SEK362.41bn (USD52.81bn) in 2014 to SEK371.80bn (USD44.94bn) in 2015; +2.6% in local currency terms and -14.9% in US dollar terms.

Contents

BMI Industry View

SWOT

Political

Economic

Operational Risk

Industry Forecast

Pharmaceutical Market Forecast

Table: Pharmaceutical Sales, Historical Data And Forecasts (Sweden 2011-2019)

Healthcare Market Forecast

Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2011-2019)

Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2011-2019)

Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sweden 2011-2019)

Prescription Drug Market Forecast

Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Sweden 2011-2019)

Patented Drug Market Forecast

Table: Patented Drug Market Indicators, Historical Data And Forecasts (Sweden 2011-2019)

Generic Drug Market Forecast

Table: Generic Drug Market Indicators, Historical Data And Forecasts (Sweden 2011-2019)

OTC Medicine Market Forecast

Table: OTC Sales by Therapeutic Group At Retail Prices, 2009-2010 (SEKmn)

Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Sweden 2011-2019)

Pharmaceutical Trade Forecast

Table: Pharmaceutical Trade Data And Forecasts (Sweden 2013-2019)

Table: Pharmaceutical Trade Data And Forecasts local currency (Sweden 2013-2019)

Key Risks To BMI's Forecast Scenario

Macroeconomic Forecasts

Economic Analysis

Policy Shifts: Two Positive, One Negative

GDP By Expenditure

Table: GDP By Expenditure (Sweden 2012-2019)

Industry Risk Reward Ratings
Western Europe Risk/Reward Index
Sweden Risk/Reward Index
Rewards
Risks
Market Overview
Industry Trends And Developments
Epidemiology
Healthcare Sector
Healthcare Financing
 Table: Healthcare Resources (Sweden 2009-2014)
 Table: Healthcare Personnel (Sweden 2009-2014)
 Table: Healthcare Activity (Sweden 2009-2014)
Research And Development
 Table: Drug Development Member Companies of SwedenBIO, 2011
Clinical Trials
Regulatory Development
Regulatory Regime
Intellectual Property Regime
Pricing Regime
Recent Pricing Developments
Reimbursement Regime
Competitive Landscape
Pharmaceutical Industry
Pharmaceuticals Manufacturing Sector
Pharmaceutical Industry Developments
Pharmaceutical Distribution
Pharmaceutical Retail Sector
 Table: Drug Retail Establishments by Type, 2006-2010
Company Profile
Meda
Swedish Orphan Biovitrum (SOBI)
Medivir
GlaxoSmithKline
Pfizer
Novartis
Sanofi
Merck & Co
AstraZeneca

Demographic Forecast

Table: Population Headline Indicators (Sweden 1990-2025)

Table: Key Population Ratios (Sweden 1990-2025)

Table: Urban/Rural Population And Life Expectancy (Sweden 1990-2025)

Table: Population By Age Group (Sweden 1990-2025)

Table: Population By Age Group % (Sweden 1990-2025)

Glossary

Methodology

Pharmaceutical Expenditure Forecast Model

Healthcare Expenditure Forecast Model

Notes On Methodology

Risk/Reward Index Methodology

Index Overview

Table: Pharmaceutical Risk/Reward Index Indicators

Indicator Weightings

I would like to order

Product name: Sweden Pharmaceuticals and Healthcare Report Q3 2015

Product link: <https://marketpublishers.com/r/SFEB59F6ACBEN.html>

Price: US\$ 1,295.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SFEB59F6ACBEN.html>